等待開盤 03-26 09:30:00 美东时间
-1.580
-9.06%
ProMIS Neurosciences (NASDAQ:PMN) reported quarterly losses of $(21.83) per share which missed the analyst consensus estimate of $(0.21) by 10295.24 percent. This is a 4266 percent decrease over losses of $(0.50) per
03-25 20:05
ProMIS Neurosciences, Inc. (NASDAQ:PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease (AD) and other neurodegenerative disorders, today announced that it will
03-18 20:03
ProMIS Neurosciences将参加2026年3月17-21日在丹麦哥本哈根举行的AD/PD™ 2026会议,展示两项科学海报,涉及其专有平台在治疗神经退行性疾病中的最新研究。本次会议将突出公司利用EpiSelect™平台开发选择性靶向有毒错误折叠蛋白的治疗方法的成果。此外,公司还将讨论其针对阿尔茨海默病的领先候选药物PMN310的最新进展。
03-18 12:00
Gainers CASI Pharmaceuticals (NASDAQ:CASI) shares rose 54.2% to $0.32 during W...
02-26 05:07
今日重点评级关注:HC Wainwright & Co.:维持NovaBridge Biosciences"买入"评级,目标价从7美元升至9美元;Truist Securities:维持Reddit"买入"评级,目标价从270美元升至275美元
02-09 14:37
Guggenheim analyst Eddie Hickman maintains ProMIS Neurosciences (NASDAQ:PMN) with a Buy and lowers the price target from $125 to $35.
02-06 22:56
ProMIS Neurosciences shares are trading higher. The company announced a $175 mi...
01-30 21:08
ProMIS Neurosciences Inc. announced the completion of a $175 million financing to extend its cash runway into 2028. The proceeds aim to complete its Phase 1b Alzheimer’s disease (AD) study and support key clinical milestones. Blinded 6-month top-line data is expected mid-2026, with 12-month data toward year-end 2026. The financing was led by Janus Henderson and Ally Bridge Group, with participation from new and existing investors, including Deep ...
01-30 13:00
Large, well-powered Phase 1b study, designed to generate clinically and biologically meaningful insights in early Alzheimer's diseaseClear and near-term value inflection points, with blinded 6-month interim data expected
2025-12-18 20:33
Results support the potential of PMN310 to improve outcomes by selectively targeting oligomers and avoiding binding to monomer and plaque ProMIS on track to complete enrollment in PRECISE-AD trial in Alzheimer's
2025-12-10 20:46